New Zealand approves MDMA for treatment of severe PTSD

New Zealand has authorized psychiatrists Dr. Gary Wynn and Dr. Tom Paterson to prescribe pharmaceutical-grade MDMA for severe PTSD, making it the second country to do so after Australia. Backed by Deputy Prime Minister David Seymour, the policy reflects a commitment to innovative therapies. While Phase 3 trials demonstrate high efficacy, the US FDA rejected similar approval in 2024 due to expectancy bias concerns. New Zealand will mandate strict, in-clinic administration combined with psychotherapy.

New Zealand MDMA regulatory approval

• ▪The Medsafe approvals were granted to Wellington psychiatrist Dr. Gary Wynn and Auckland psychiatrist Dr. Tom Paterson, who spent over a year navigating the regulatory process.
• ▪New Zealand is the second country globally to authorize MDMA for clinical use, following Australia's approval of the substance in 2023.
• ▪New Zealand's medicines regulator, Medsafe, approved two psychiatrists on September 4, 2026, to prescribe pharmaceutical-grade MDMA to patients with severe post-traumatic stress disorder.

PTSD treatment efficacy trials

• ▪A 2023 Phase 3 clinical trial sponsored by Lykos Therapeutics found that 71.2% of participants with moderate-to-severe PTSD treated with MDMA no longer met PTSD diagnostic criteria by the study's end.
• ▪A 2025 study in Israel found that MDMA taken by partygoers during the October 7 Hamas attack at the Nova music festival helped cushion the impact of their trauma.
• ▪A 2021 Phase 3 clinical trial sponsored by Lykos Therapeutics found that 88% of participants with severe PTSD receiving MDMA-assisted therapy showed clinically significant improvement, and 67% no longer met PTSD diagnostic criteria.

US FDA rejection concerns

• ▪The United States Food and Drug Administration rejected the approval of MDMA-assisted therapy in 2024, citing insufficient evidence of safety and effectiveness.
• ▪United States regulators raised concerns that trial participants who had previously taken MDMA produced an expectancy bias, which complicated the clinical trial data.

Clinical setting treatment protocols

• ▪New Zealand's Ministry of Health confirmed that patients will not receive take-home doses of MDMA, and treatment must occur in a controlled clinical setting under an authorized psychiatrist.
• ▪New Zealand's Ministry of Health stated that MDMA-assisted treatment will be combined with psychotherapy and administered only to patients aged 18 or older.

Psychedelic therapy policy expansion

• ▪New Zealand Deputy Prime Minister David Seymour previously backed the approval of psilocybin, the active compound in magic mushrooms, in 2025 to treat severe depression.
• ▪New Zealand Deputy Prime Minister David Seymour supported the MDMA approval, stating that the country is committed to opening access to innovative treatments.

3 sources